Sylvia Adams

Sylvia Adams is a breast cancer immunologist and oncologist specializing in triple-negative breast cancer immunotherapy. She has conducted foundational research on tumor-infiltrating lymphocytes in TNBC and their role in predicting immunotherapy response. Her laboratory and clinical trials have investigated PD-1/PD-L1 checkpoint inhibitors in early and metastatic TNBC, contributing to understanding of which patients benefit most from immunotherapy. She has been a key investigator in multiple immunotherapy trials in breast cancer and serves on major oncology guideline committees.